SOURCE: Bio-Matrix Scientific Group, Inc.

October 09, 2013 15:11 ET

Bio-Matrix Scientific Group Inc. Announces 20 Million Share Regen BioPharma Dividend to Be Paid to Shareholders

Dividend Is Approximately 40% Payout of Regen's Issued and Outstanding Shares

SAN DIEGO, CA--(Marketwired - Oct 9, 2013) - Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN) today announced that its Board of Directors has authorized a distribution on a pro rata basis as a dividend in kind of 20,000,000 of the common shares of Regen BioPharma Inc. ("Dividend Shares"), a subsidiary of BMSN, to:

(a) Holders of record of the outstanding common shares of BMSN as of the record date

(b) Holders of record of the shares of any outstanding series of the preferred shares of BMSN as of the record date.

Bio-Matrix' Chairman & CEO David Koos stated, "The record date is anticipated to be set as soon as possible after the Form S-1 registering the Dividend Shares under the Securities Act of 1933 is declared effective by the United States Securities and Exchange Commission (SEC). On a pro rata basis, both common and all classes of preferred shareholders will receive this dividend. The Company expects the registration statement to be filed within the next few days with the SEC."

There are 51,610,000 currently outstanding in Regen BioPharma Inc., with Bio-Matrix Scientific Group Inc. owning 50,010,000 of these common shares.

About Regen BioPharma: Regen BioPharma, Inc., a subsidiary of Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN), is a biotechnology company focused on identifying undervalued regenerative medicine applications in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. For more information refer to the company's website

Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Contact Information

  • Contact:

    Bio-Matrix Scientific Group, Inc. and
    Regen BioPharma Inc.
    David R. Koos, PhD
    Chairman & Chief Executive Officer